(f) It would be more easy and effective to activate inflammation or other mechanisms for endogenous stem cell recruitment and proliferation.
In other terms, should we stimulate the physiological role of endogenous stem cells instead of their grafting? (g) The research of "ideal" stem cells, with a full and standardized characterization/selection is difficult to be followed and requires high costs that cannot be supported, using the actual technology. Can we overcome this step?
In our opinion researchers must change their traditional approaches if the goal of a large-scale use of stem cells is compulsory.
This does not imply that basic studies on biology of stem cells must not be done: they should continue, independently from the practical use of stem cells, which, on the other hand, cannot wait for more.
Moreover, the studies on non-human stem cells (i.e. rat, mice, and other animals) must be reduced to the minimum, this because those cells show many differences with human stem cells and we need to study more human stem cells.
We are sure that our goal are patients, while several animal stem cells features or proteins or other features cannot be found in human stem cells.
In summary, a great effort must be tried in order to avoid that we will acquire a lot of knowledge but no translation of studies in patients will be performed.
The latter would really be a great failure or "default." To date many articles and reviews have been devoted to the use of stem cells in regenerative medicine. Of the previous, some articles, about 20%, are interesting and constitute an advance in knowledge, the majority (50%) are of marginal interest, and some (30%) are completely not useful, although they can be found in literature.
The emerging major problems affecting the impact of this field in patient's cure can be mainly found in the high costs of procedures and in other problems that need to be fully addressed by the scientific community, that we evidence below.
The following major questions must be still addressed for a true enhancement of the practical use of stem cells in patient's cure:
(1) New methods for GMP stem cell cultures, dedicated to grafts, must be used, including, for instance, microgravity, omega3 fatty acids, new oxygen bioreactors; this is a major point, of interest and that can be addressed by both biologists, physicians, and engineers; (2) Ascertain genetic stability of stem cells before and after grafting is another key step. A schedule should be delivered and published on this issue by researchers, often after having obtained data of graft trials; (3) The problem of quality and quantity of cells must be unambiguous and a general rule established. Many researchers try to demonstrate the purity of stem cell populations and try to obtain a translation of their findings. This point presents several ambiguities, mainly residing in the purity judgment itself; (4) 
